Citation:Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavolé A, et al 2011

From Cancer Guidelines Wiki

Citation


Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavolé A, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011 Sep 17;378(9796):1079-88 Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/21831418.



Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
What is the optimal systemic therapy for stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted
Which new agent or platinum combination regimen is best for treatment of stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted
Is monotherapy with new third generation (3G) agents as effective as platinum combination therapy for treatment of stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted
What is the optimal systemic therapy regimen for patients with poor performance status for treatment of stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted
What is the optimal systemic therapy regimen for elderly patients for treatment of stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted

Compare quality appraisals for each clinical question

Cited by

  1. What is the optimal systemic therapy for stage IV inoperable NSCLC?
  2. What is the optimal systemic therapy regimen for elderly patients for treatment of stage IV inoperable NSCLC?